These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35673964)

  • 21. Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States.
    Harris L; Allman PH; Sheffield R; Cutter G
    J Clin Neuromuscul Dis; 2020 Sep; 22(1):11-21. PubMed ID: 32833720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
    Mullaney P; Vajsar J; Smith R; Buncic JR
    Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Myasthenia Gravis-specific Activities of Daily Living scale as a useful outcome measure and in routine clinical management in Polish patients.
    Rozmilowska IM; Adamczyk-Sowa MH; Czyzewski D
    Neurol Neurochir Pol; 2018; 52(3):368-373. PubMed ID: 29370887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.
    de Meel RHP; Raadsheer WF; van Zwet EW; Verschuuren JJGM; Tannemaat MR
    Eur J Neurol; 2019 Jun; 26(6):947-950. PubMed ID: 30417962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymectomy for myasthenia gravis.
    Blossom GB; Ernstoff RM; Howells GA; Bendick PJ; Glover JL
    Arch Surg; 1993 Aug; 128(8):855-62. PubMed ID: 8343058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
    Chirapapaisan N; Tanormrod S; Chuenkongkaew W
    Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overactive bladder in patients with myasthenia gravis-A cross-sectional population-based study.
    Donskov AO; Vinge L; Axelsen SM; Andersen H
    Acta Neurol Scand; 2021 Jul; 144(1):76-80. PubMed ID: 33772766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Newly diagnosed multiple sclerosis in a patient with ocular myasthenia gravis: A case report.
    Bong JB; Lee MA; Kang HG
    Medicine (Baltimore); 2022 Feb; 101(8):e28887. PubMed ID: 35212290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
    Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
    Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
    Singer M; Khella S; Bird S; McIntosh P; Paudyal B; Wadhwani A; Quinn C; Karam C
    Muscle Nerve; 2024 Jan; 69(1):87-92. PubMed ID: 37990374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
    Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
    Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU).
    Hehir MK; Conaway M; St Sauveur AB; Feb K; Kolb NA; Waheed W; McNeish BL; Tweedy N; Burns TM
    Muscle Nerve; 2024 Jan; 69(1):32-39. PubMed ID: 37676119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study.
    Andersen JB; Owe JF; Engeland A; Gilhus NE
    Eur J Neurol; 2014 Jul; 21(7):948-55. PubMed ID: 24712740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myasthenia Symptom Burden, Fatigue, and Sleep: Are They Related?
    Yang S; Miglis MG; Jaradeh S; Muppidi S
    J Clin Neuromuscul Dis; 2021 Mar; 22(3):123-128. PubMed ID: 33595995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
    Kupersmith MJ; Ying G
    Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Major review: the clinical spectrum of pediatric myasthenia gravis: blepharoptosis, ophthalmoplegia and strabismus. A report of 14 cases.
    McCreery KM; Hussein MA; Lee AG; Paysse EA; Chandran R; Coats DK
    Binocul Vis Strabismus Q; 2002; 17(3):181-6. PubMed ID: 12171588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myasthenia gravis in Jamaican children: a 12-year institutional review.
    Melbourne Chambers R; Forrester S; Gray R; Tapper J; Trotman H
    Paediatr Int Child Health; 2012 Feb; 32(1):47-50. PubMed ID: 22525448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Childhood myasthenia gravis: clinical features and outcomes.
    Sri-udomkajorn S; Panichai P; Liumsuwan S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.